Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3 ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection Olpasiran to reduce production of apolipoprotein A and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.